The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
Open accessAbstract
We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V 1a , V 1b and V 2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT). In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents. We also present our recent findings on the design of fluorescent ligands for V 1b receptor localisation and for OT receptor dimerisation. We note the exciting discoveries regarding two novel naturally occurring analogues of OT. Recent reports of a selective VP V 1a agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field. To date, only two nonpeptides, the V 2 /V 1a antagonist, conivaptan and the V 2 antagonist tolvaptan have received Food and Drug Administration approval for clinical use. The development of nonpeptide AVP V 1a , V 1b and V 2 antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer. A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clinical trial for the prevention of premature labour. A number of the nonpeptide ligands that were not successful in clinical trials are proving to be valuable as research tools. Peptide agonists and antagonists continue to be very widely used as research tools in this field. In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, especially with regard to receptor selectivity and species differences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although these compounds bind selectively to their respective receptors in rodents, they have now been shown to exhibit relatively high affinities for both OXTR and AVPR1a in primates (27,28).”
From Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications (2016) · cites this paper as [28]
In the citing paper
“Simply comparing the binding characteristics of the most common ligands for the human and rat OT and AVP receptors reveals considerable variation in pharmacological properties across species (28).”
From Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications (2016) · cites this paper as [28]
In the citing paper
“For example, studies employing recombinant expression systems to examine selectivity of human, rat, and mouse OT and AVP receptors have shown that only the human OTR is selective for OT using a standard criterion [34; 35] (Table 1).”
From Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery (2018) · cites this paper as [35]
In the citing paper
“The limited information on the distributions of OTR and V1aR in primate neural tissue is due in part to the lower selectivity for radioligands targeting OTR (125I-OVTA) and V1aR (125I-LVA) autoradiography, relative to high selectivity of radioligands for these receptors in rodents, as well as the promiscuous binding profile of both radioligands for OTR and V1aR (Freeman et al., 2014a, 2014b; Man”
From Neuropeptide diversity and the regulation of social behavior in New World primates (2016) · cites this paper as Manning et al., 2012
In the citing paper
“There was also no difference in AVP levels, suggesting no peripheral cross-reactivity, which is more likely to occur with higher levels of oxytocin exposure.71”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–244 of 244
Manning, M., Misicka, A., Olma, A., Kliś, W. A., Bankowski, K., Nawrocka, E., Kruszynski, M., Kolodziejczyk, A., & Cheng, L. (1987) · Journal of Medicinal Chemistry · doi:10.1021/jm00395a012 · Cited by 31
Self-citationBeyer, C. E., Dwyer, J. M., Platt, B. J., Webb, S. J. N., Luo, B., Ling, H., Lin, Q., Mark, R. J., Rosenzweig-Lipson, S. J., & Schechter, L. E. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1791-1 · Cited by 30
Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients
Naidech, A. M., Paparello, J. J., Leibling, S. M., Bassin, S. L., Levasseur‐Franklin, K. E., Alberts, M. J., Bernstein, R. A., & Muro, K. (2010) · Neurocritical Care · doi:10.1007/s12028-010-9379-5 · Cited by 29
Cudnoch‐Jędrzejewska, A., Szczepanska‐Sadowska, E. K., Dobruch, J. T., Gomolka, R. S., & Puchalska, L. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00543.2009 · Cited by 29
Manning, M., Bańkowski, K., Barberis, C., Jard, S., Elands, J., & Chan, W. Y. (1992) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1992.tb00300.x · Cited by 29
Self-citationComparison of Alexa Fluor® and CyDye™ for practical DNA microarray use
Ballard, J. L., Peeva, V. K., deSilva, C. J. S., Lynch, J. L., & Swanson, N. R. (2007) · Molecular Biotechnology · doi:10.1007/s12033-007-0006-4 · Cited by 28
Potent V2 vasopressin antagonists with structural changes at their C-terminals
Sawyer, W. H., Bańkowski, K., Misicka, A., Nawrocka, E., Kruszynski, M., Stoev, S., Kliś, W. A., Przybylski, J., & Manning, M. (1988) · Peptides · doi:10.1016/0196-9781(88)90022-8 · Cited by 27
Self-citationOxytocin-Gly-Lys-Arg: A Novel Cardiomyogenic Peptide
Danalache, B. A., Gutkowska, J., Ślusarz, M. J., Berezowska, I., & Jankowski, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013643 · Cited by 26
Frantz, M., Rodrigo, J., Boudier, L., Durroux, T., Mouillac, B., & Hibert, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901084f · Cited by 26
Self-citationNakamura, K., Fujiwara, Y., Mizutani, R., Sanbe, A., Miyauchi, N., Hiroyama, M., Yamauchi, J., Yamashita, T., Nakamura, S., Mori, T., et al. (2008) · Endocrinology · doi:10.1210/en.2007-1528 · Cited by 25
Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin
Manning, M., Kliś, W. A., Kruszynski, M., Przybylski, J., Olma, A., Wo, N. C., Pelton, G. H., & Sawyer, W. H. (1988) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1988.tb01376.x · Cited by 25
Self-citationCorbani, M., Trueba, M., Stoev, S. B., Murat, B., Mion, J., Boulay, V., Guillon, G., & Manning, M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1016208 · Cited by 25
Self-citationSynthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography
Schönberger, M., Leggett, C. S., Kim, S. W., & Hooker, J. M. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.108 · Cited by 24
Rehberg, S. W., Ertmer, C., Lange, M., Morelli, A., Whorton, E. B., Dünser, M. W., Strohhäcker, A.-K., Lipke, E., Kampmeier, T., Aken, H. V., et al. (2010) · Critical Care · doi:10.1186/cc9320 · Cited by 23
Veitenheimer, B., & Osborn, J. W. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00371.2010 · Cited by 22
Teruyama, R., Lipschitz, D. L., Wang, L., Ramoz, G., Crowley, W. R., Bealer, S. L., & Armstrong, W. E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90620.2008 · Cited by 22
Biologic assays for oxytocin and vasopressin.
Wh, S. (1961) · PubMed · Cited by 22
Structure–Activity Relationships of Neurohypophyseal Peptides
Hruby, V. J., & Smith, C. W. (1987) · Elsevier eBooks · doi:10.1016/b978-0-12-304208-8.50008-x · Cited by 21
Waldherr, M., Nyuyki, K. D., Maloumby, R., Bosch, O. J., & Neumann, I. D. (2009) · Hormones and Behavior · doi:10.1016/j.yhbeh.2009.11.006 · Cited by 20
Northrop, L. E., & Erskine, M. S. (2007) · Endocrinology · doi:10.1210/en.2007-1040 · Cited by 18
Altshuller, D. A. (2012) · Lecture notes in control and information sciences · doi:10.1007/978-1-4471-4234-8_1 · Cited by 17
Searcy, B. T., Bradford, C. S., Thompson, R. R., Filtz, T. M., & Moore, F. L. (2010) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2010.09.017 · Cited by 16
Kwiatkowska, A., Sobolewski, D., Prahl, A., Borovičková, L., Slaninová, J., & Lammek, B. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.12.010 · Cited by 16
(2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511760334 · Cited by 15
Tanoue, A. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08r15fm · Cited by 15
Tolvaptan, hyponatremia, and heart failure
Zmily, H. D., Daifallah, S., & Ghali, J. K. (2011) · Dove Medical Press (Taylor and Francis Group) · Cited by 15
Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids
Manning, M., Przybylski, J., Grzonka, Z., Nawrocka, E., Lammek, B., Misicka, A., Cheng, L., Chan, W. Y., Wo, N. C., & Sawyer, W. H. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00099a018 · Cited by 14
Self-citationDevelopment of vasopressor specific vasotocin analogues with prolonged effects
Aurell, C., Bengtsson, B. Å., Ekholm, K., Kasprzykowska, R., Nilsson, A., Persson, R., Trojnar, J., Abbe, M., & Melin, P. (1991) · Springer eBooks · doi:10.1007/978-94-011-3034-9_278 · Cited by 14
G Protein-Coupled Receptors: Structure, Signaling, and Physiology.
Teixeira, A. (2011) · PubMed Central · Cited by 13
Busnardo, C., Tavares, R. F., & Corrêa, F. M. D. A. (2008) · Autonomic Neuroscience · doi:10.1016/j.autneu.2008.11.005 · Cited by 13
Dyckes, D. F., Ferger, M. F., du Vigneaud, V., & Chan, W. Y. (1973) · Journal of Medicinal Chemistry · doi:10.1021/jm00265a022 · Cited by 13
Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms
Andrés, M., Peña, A., Derick, S., Raufaste, D., Trojnar, J., Wiśniewski, K., Trueba, M., Gal, C. S., & Guillon, G. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.08.026 · Cited by 13
Self-citationOxytocin increases 5α‐reductase activity of human prostate epithelial cells, but not stromal cells
Assinder, S. J. (2007) · The Prostate · doi:10.1002/pros.20671 · Cited by 12
Agonist-specific requirement for a glutamate in transmembrane helix 1 of the oxytocin receptor
Wootten, D. L., Simms, J., Massoura, A. J., Trim, J. E., & Wheatley, M. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.11.029 · Cited by 11
Mechanism of 1-deamino-arginine vasotocin induced natriuresis in rats
Karavashkina, T. A., Кутина, А. В., Ei, S., & IuV, N. (2010) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2010.10.020 · Cited by 11
Guillon, G., Peña, A., Murat, B., Derick, S., Trueba, M., Ventura, M. A., Szeto, H. H., Wo, N. C., Stoev, S. B., Cheng, L., et al. (2005) · Journal of Peptide Science · doi:10.1002/psc.710 · Cited by 11
Self-citationMagafa, V., Borovičková, L., Slaninová, J., & Cordopatis, P. A. (2009) · Amino Acids · doi:10.1007/s00726-009-0372-2 · Cited by 10
Vasopressin antagonists in hyponatremia: more data needed
Sterns, R. H., & Hix, J. K. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.173 · Cited by 9
DeVries, A. C., Norman, G. J., Karelina, K., Morris, J., Zhang, N., & Cochran, M. (2010) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2010.07.118 · Cited by 7
Manning, M. (2007) · Biopolymers · doi:10.1002/bip.20802 · Cited by 7
Self-citationShirley, D. G., Walter, M. F., Keeler, B. D., Waters, N. J., & Walter, S. J. (2010) · Nephron Physiology · doi:10.1159/000320290 · Cited by 7
Russell, R. J., Doyle, R., Turner, J., Attkins, N. J., Ramsey, S. J., Weibley, L., Bateman, L., Bictash, M., Neal-Morgan, S., Ivarsson, M., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.09.034 · Cited by 3
Vasotocin- and mesotocin-induced increases in short-circuit current across tree frog skin
Takada, M., Fujimaki-Aoba, K., & Hokari, S. (2010) · Journal of Comparative Physiology B · doi:10.1007/s00360-010-0523-5 · Cited by 3
Ślusarz, R., & Ślusarz, M. J. (2009) · QSAR & Combinatorial Science · doi:10.1002/qsar.200810164 · Cited by 2
Flagged first, then by citations
Research works printed but not linked: 13
- Manning M, 1981, The Pituitary, 265
- Manning M, 1985, Development of Selective Agonists and Antagonists of Vasopressin and Oxytocin, 131
- Manning M, 1991, Vasopressin, 297
- Manning M, 2005, Peptides 2004, 101
- Lebl M, 1988, Handbook of Neurohypophyseal Hormone Analogs, 17
- Jard S, 1998, Adv Exp Med Biol, 1
- 10.1210/en.137.9.3906 · DOI
- Wisniewski K, 2010, Peptides 2010, 306
- Manning M, 2010, Peptides 2010, 366
- Guillon G, 2007, Peptides 2006, 742
- 10.1021/jm010526 · DOI
- Mimoun MB, 2001, Peptides 2000, 589
- Reichert J, 2010, Development Trends for Peptide Therapeutics
Cited by
Sorted by citations
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 2,074
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,150
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 561
Dumais, K. M., & Veenema, A. H. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2015.04.003 · Cited by 520
“However, this study used [3H] OT and, like [3H] VP, [3H] OT may not exclusively bind OTR (Mouillac et al., 1995; Manning et al., 2012), and thus possibly may mask potential sex differences in OTR binding.”
MethodNeuromodulation by Oxytocin and Vasopressin
Stoop, R. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.025 · Cited by 506
Metadata
- Authors
- Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G.
- Affiliations
- University of Toledo (US)
- University of Warsaw (PL)
- Lodz University of Technology (PL)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Manning, M.
- Venue
- Journal of Neuroendocrinology
- Publisher
- Wiley
- Published
- 2012-03-26
- Volume
- 24
- Issue
- 4
- Pages
- 609-628
- ISSN
- 0953-8194 (ISSN-L)
- 1365-2826
- PMC
- PMC3490377
- OpenAlex
- W1803779312
- Cited by
- 423
- References
- 244
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 22 · 2023: 25 · 2022: 32 · 2021: 36 · 2020: 31 · 2019: 40 · 2018: 34 · 2017: 35 · 2016: 28 · 2015: 29 · 2014: 38 · 2013: 30 · 2012: 8
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuroendocrinology (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Centre National de la Recherche Scientifique
- National Institute of General Medical Sciences (GM25280, R01GM025280)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- oxytocin, vasopressin, vasopressin receptor, oxytocin receptor, V1a receptor, V1b receptor, V2 receptor, peptide agonists, peptide antagonists, conivaptan, tolvaptan, fluorescent ligands, receptor localization, receptor dimerization, oxytocin analogues, receptor selectivity, species differences
- MeSH terms
- Animals, Arginine Vasopressin, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Oxytocin, Structure-Activity Relationship, Receptors, Vasopressin, Receptors, Oxytocin, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
